A New Hope for Pancreatic Cancer: PARP Inhibition in Tumors With BRCA Mutations

Learn about PARP inhibition in BRCA-positive pancreatic cancer from 3 renowned experts.
John L. Marshall, MD
Program Director
Tanios Bekaii-Saab
Tanios Bekaii-Saab, MD, FACP
Eileen M. O'Reilly, MD
Released: March 8, 2019 Expiration: No longer available for credit

Related Content

From Clinical Care Options, Zofia Piotrowska, MD, MHS, and Stephen V. Liu, MD, review key data from studies of lung cancer treatment presented at ASCO 2020

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 25, 2020 Expired: September 24, 2021

Gain key clinical insights fast, with this short slideset from CCO on lung cancer data presented at 2020 ASCO

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Released: September 25, 2020

In this slideset from Clinical Care Options (CCO), experts provide insights on HER2 testing and targeted therapy in advanced gastrointestinal cancers

Axel Grothey Headshot Axel Grothey, MD Michael F. Press, MD, PhD Released: September 25, 2020

Downloadable slideset covering the latest data on treating patients with pancreatic cancer and BRCA mutations or other actionable alterations, from Clinical Care Options (CCO)

person default Dirk Arnold, MD, PhD Released: September 21, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue